Skip Navigation


QJM Advance Access originally published online on May 25, 2007
QJM 2007 100(7):415-422; doi:10.1093/qjmed/hcm040
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/7/415    most recent
hcm040v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Thomson, P.C.
Right arrow Articles by Mactier, R.A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Thomson, P.C.
Right arrow Articles by Mactier, R.A.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Vascular access in haemodialysis patients: a modifiable risk factor for bacteraemia and death

P.C. Thomson, C.M. Stirling, C.C. Geddes1, S.T. Morris and R.A. Mactier

From the Renal Unit, Glasgow Royal Infirmary, and 1Renal Unit, Western Infirmary, Glasgow, UK

Address correspondence to Dr P. Thomson, Renal Unit, 3rd Floor Walton Building, Glasgow Royal Infirmary, 84 Castle Street, Glasgow G4 OSF. e-mail: peter.thomson{at}northglasgow.scot.nhs.uk

Received 18 October 2006 and in revised form 14 February 2007


   Abstract

Background: Bacteraemia and the development of sepsis syndrome is second only to cardiovascular disease as the leading cause of death in patients on renal replacement therapy.

Aim: To determine the contributions of laboratory and clinical variables to the risk of bacteraemia and death in haemodialysis patients.

Design: Retrospective analysis.

Methods: We analysed all patients receiving haemodialysis in our renal unit at the beginning of January 2004 (n = 263), recording clinical and laboratory variables for each patient at study entry. Bacteraemia and mortality were recorded for the subsequent 18-month period. Multivariate analysis using a Cox proportional hazards model was used to test for independent associations between variables and outcomes.

Results: During the study period, 45 patients (17.1%) developed bacteraemia and 65 (24.7%) died. Under multivariate analysis, use of dialysis catheters at study entry was a major factor in the development of bacteraemia and death with hazard ratios (HR) of 5.4 (p < 0.001) and 2.8 (p = 0.012), respectively, for tunnelled central venous catheters vs. arteriovenous fistulas (AVFs) and 3.1 (p = 0.01) and 3.4 (p = 0.001), respectively, for non-tunnelled central venous catheters vs. AVFs. Elevated CRP at study entry was independently associated with bacteraemia (HR 1.5 per unit log-CRP, p = 0.006). Low serum albumin (HR 0.92, p = 0.005) was independently associated with death.

Discussion: Use of synthetic vascular access catheters and heightened inflammatory state both have strong independent associations with subsequent bacteraemia and death. Bacteraemia surveillance strategies should be developed, with consideration of vascular access type and baseline inflammatory state as key components.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.